What's hot!

View all perspectives
What's Hot

Dietary Interventions in PsA

Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.

Watch video →

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise

Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. 

Watch video →

Renal Biopsies in SLE

Dr. Andrea Fava reporting from EULAR 2026 in London.

Watch video →

RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk

Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London 

Watch video →

Combination Biologics in PsA: MRI Findings from AFFINITY

Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.  

Watch video →

Day 4 Recap: EULAR 2026

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.

Watch video →

EULAR 2026 Recommendations: Immunization

Dr. Jiha Lee reporting from EULAR 2026 in London.

Watch video →

Making Methotrexate More Effective

Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London

Watch video →

Are we failing in the treatment of RA-ILD?

Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.

Watch video →

How Many CAR-Ts Do We Need to Test Drive?

Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.

Watch video →

Day 3 Recap: EULAR 2026

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288

Watch video →

New axSpA Criteria: Who gets left out?

Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.  

Watch video →

PsA Potpourri: Probiotics & Head-to-Head Data

Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.

Watch video →
CAR T on purple background

5 years since Patient ID001: Progress on CAR-T Therapy in RMD

Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?

Read more →

BMI Outranks Treatment in PsA Outcomes?

Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.

Watch video →

BE BOLD: Going Where No PsA Trial Has Gone Before

Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London  

Watch video →
holding hands together support frail

New biomarkers in RA: Who to treat, Who to watch, Who to taper?

Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.

Read more →

Debate: Combination Therapies for Inflammatory Arthritis?

Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.

Watch video →
      Ivarmacitinib (selective oral JAKi) in active nr-axSpA:
      This ph3 RCT showed that Ivarmacitinib 4mg significantly improve

      sheila RHEUMarampa

      1 week 1 day ago
      Ivarmacitinib (selective oral JAKi) in active nr-axSpA: This ph3 RCT showed that Ivarmacitinib 4mg significantly improved s/sxs & dse act vs. PBO at wk 12 (39.7% vs 24.8%; P=0.0057) and maintained until wk 24 Interesting. A new JAKi option for axSpA OPO237 @RheumNow #EULAR2026 https://t.co/bxbO8GfegP
      #OP0222 at #EULAR2026: ReBioLup highlights the disconnect between proteinuria & histopathological activity in lupus

      Mrinalini Dey DrMiniDey

      1 week 1 day ago
      #OP0222 at #EULAR2026: ReBioLup highlights the disconnect between proteinuria & histopathological activity in lupus nephritis. 73% of patients with persistent histologic activity at 12 months still met criteria for complete clinical response. @RheumNow https://t.co/VxgT6812VO
      ASAS-SPARTAN revised #axSpA classification criteria have hug specificity (>94%) but lower sensitivity than the 2009 c

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      ASAS-SPARTAN revised #axSpA classification criteria have hug specificity (>94%) but lower sensitivity than the 2009 criteria, excluding ~27% of patients classified by the older criteria Abstr OP239 @RheumNow #EULAR2026 https://t.co/vGJN8eEKKh
      Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026
      #OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in rout

      Mrinalini Dey DrMiniDey

      1 week 1 day ago
      #OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow
      #EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.?

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 1 day ago
      #EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB
      #OP006 - Urine proteomics in LN tracks histo activity & treatment response better than proteinuria.Paired biopsies

      Mrinalini Dey DrMiniDey

      1 week 1 day ago

      #OP006 - Urine proteomics in LN tracks histo activity & treatment response better than proteinuria. Paired biopsies linked active disease to IFNI, IL12, complement & neut pathways- normalised in responders but persisted in non-responders. @RheumNow #EULAR2026 #EULARBest #Plenary

      #EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 1 day ago
      #EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy and Safety of Ianalumab in #Sjogren disease #SjD @RheumNow https://t.co/NEyBOD6Qj2 https://t.co/Zn1fH6eu39
      💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr?

      Phase2b/3 RCT: ~50% ACR50 at week in 343pts

      OP073 #EULAR2026 @R

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr? Phase2b/3 RCT: ~50% ACR50 at week in 343pts OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c
      🔬 Does synovial biopsy-guided treatment outperform standard care in PsA?

      YES - 68% vs 45% DAPSA remission/LDA in 45p

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      🔬 Does synovial biopsy-guided treatment outperform standard care in PsA? YES - 68% vs 45% DAPSA remission/LDA in 45pts OP071 #EULAR2026 @RheumNow https://t.co/cLCR7I8QAm
      #Rosnilimab works!! #PD1 agonist
      In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoi

      Janet Pope Janetbirdope

      1 week 1 day ago
      #Rosnilimab works!! #PD1 agonist In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA #EULAR2026 @RheumNow #OP0202 #EULARbest https://t.co/Jz92npXdgd
      SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA

      Confirms what we already knew:

      -

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA Confirms what we already knew: -Primary endpoint CDAI change wk26 not different -Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034 -Better response in https://t.co/002n3sWtKs
      Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placeb

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026
      Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow
      🤰What happens to RA disease activity during pregnancy?

      🔴 Most remain stable
      🔴 70% with high disease activity

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      🤰What happens to RA disease activity during pregnancy? 🔴 Most remain stable 🔴 70% with high disease activity at baseline improve 🔴 20% flare again post-partum ✨ACPA+ improve more ✨ Better outcomes after 2016 (after modern treatments) OP0242 #EULAR2025 @rheumnow https://t.co/i3X566DcN6

      Podcasts

      • RA Topic Podcast compilation
      • PsA Topic Podcast compilation
      • CAR T Topic compilation

      Catch up on Conference Podcasts

      ×